Enterprise Value
-36.39M
Cash
94.69M
Avg Qtr Burn
-25.94M
Short % of Float
7.14%
Insider Ownership
14.71%
Institutional Own.
64.61%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Korsuva IV (CR845 IV) Details Pruritus with chronic kidney disease , Kidney disease | Approved Quarterly sales | |
Oral Korsuva (difelikefalin) (CR845) Details Pruritus with chronic kidney disease , Chronic kidney disease | Phase 3 Data readout | |
Oral Korsuva (difelikefalin)(CR845) Details Skin disease/disorder, Inflammatory disease, Atopic dermatitis, Atopic pruritus Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Oral Korsuva (difelikefalin) (CR845) Details Chronic pruritus, Pruritus associated with notalgia paresthetica | Phase 2/3 Data readout | |
Oral Korsuva (difelikefalin) (CR845) Details Chronic liver disease, Liver disease, Chronic pruritus, Hemophilia, Blood disorder | Failed Discontinued |